Innocan Pharma Corporation (CSE:INNO) said Tuesday that clinical studies have demonstrated the effectiveness of the firm’s SHIR CBD facial serum on skin hydration.
The study looked at the impact of SHIR, which contains 300 milligrams of CBD, on hydration levels by measuring the skin capacitance periodically up to 24 hours after the serum was applied.
Results indicated significant hydration increases for each two-, four-, eight, and 24-hour period after application, according to a release from Innocan. In addition, the serum was well tolerated with no uncomfortable symptoms reported by participants.
READ: Innocan Pharma strikes deal to distribute its SHIR line of CBD beauty products in Italy and Switzerland
All of the SHIR Derma Cosmetic products tested to date have demonstrated to be non-irritating in clinical testing, according to Israel-based Innocan.
CEO Iris Bincovich told investors that the results demonstrate the efficacy of the product.
"Hydrating the skin is one of the most crucial measures to keep the skin healthy, young and also to eliminate wrinkles,” Bincovich said in a statement.
“The amazing results of the new clinical studies are in addition to Innocan's research and development efforts to bring to market, a trustworthy product that will set a new industry standard.”
SHIR skincare products combine the benefits of CBD with the most effective ingredients in an innovative formula to deliver visible results.
Contact Angela at firstname.lastname@example.org
Follow her on Twitter @AHarmantas